Antibody Conjugation via Solid-Phase Immobilization for ADC Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for screening antibodies for use as antibody-drug conjugates (ADCs) are limited by low yields from conventional conjugation methodologies, especially when dealing with microgram quantities, and indirect assays can be misleading due to crosslinking effects and affinity constraints.
Innovation Solution
The development of methods involving immobilization of antibodies on a solid support, selective reduction of disulfide bonds, and reaction with capping agents, drugs, or detection agents to achieve uniform drug loading and direct cytotoxic activity assessment, allowing for high-throughput screening of antibody panels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional conjugation methodologies are used, then the process is simple, but the yield is low when dealing with microgram quantities
Solution Approach 1:
The patent applies preliminary action by immobilizing antibodies on solid supports before conjugation. This pre-positioning allows subsequent reagents to be added in a fixed sequence without requiring complex real-time monitoring or adjustments, thereby improving yield while maintaining procedural simplicity
Solution Approach 2:
The patent introduces solid supports as intermediaries between the antibody and the conjugating reagents. These solid supports facilitate the conjugation process by providing a stable platform that enhances reaction efficiency and yield, particularly for microgram quantities, without significantly increasing overall process complexity
2Measurement precision
If indirect assays with secondary antibodies are used, then the screening process is simplified, but the results become misleading due to crosslinking effects and affinity constraints
Solution Approach 1:
The patent extracts the problematic secondary antibody step from the assay process and replaces it with direct detection methods. By removing the intermediary secondary antibody that causes crosslinking artifacts, the assay maintains simplified procedures while achieving accurate, artifact-free results
Solution Approach 2:
The patent creates a simplified copy of the conjugation process on solid supports that directly reflects the actual ADC formation without the complicating factors of solution-phase crosslinking. This solid-phase model provides accurate measurements while maintaining assay simplicity
3Measurement precision
If a large antibody panel is screened in the form of ADCs, then direct measurement of cytotoxic activity parameters is achieved, but the low yield from conventional conjugation limits the screening capacity
Solution Approach 1:
The patent segments the conjugation process into discrete solid-phase steps that can be performed in parallel across multiple samples. This segmentation allows simultaneous processing of large antibody panels, achieving both direct measurement accuracy and high screening throughput by dividing the workflow into independent, scalable units
Solution Approach 2:
The patent transitions from solution-phase conjugation to solid-phase conjugation, adding the spatial dimension of immobilization. This dimensional change enables high-throughput processing by allowing simultaneous conjugation of multiple antibodies on separate solid supports, thereby increasing screening capacity while maintaining direct measurement capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables efficient and accurate screening of antibodies for ADCs, overcoming yield limitations and assay inaccuracies, facilitating the identification of antibodies with desired cytotoxic activities.
Implementation Method 1
immobilizing the antibodies on a solid support
Implementation Method 2
reacting the reduced immobilized antibodies with capping agent, drug or drug-linker
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention provides methods for making antibody conjugates for use in antibody screening assays and antibody conjugates produced by the claimed methods.